Award
National Institute of Neurological Disorders and Stroke 5R01NS136281-03
Laminin protein therapy for the treatment of Laminin-alpha2 deficient congenital muscular dystrophy
Recipient
University of Nevada Reno
Award Amount
$413,661.00
Ceiling
$413,661.00
Awarded
March 31, 2026
Identifier
5R01NS136281-03
This NIH-funded project investigates recombinant human laminin protein therapy as a treatment for Laminin-alpha2 deficient congenital muscular dystrophy, targeting muscle repair and neuromuscular improvement.
Description
Research project focused on developing recombinant human laminin protein therapy to treat Laminin-alpha2 deficient congenital muscular dystrophy, aiming to restore muscle extracellular matrix, promote muscle regeneration, and improve neuromuscular function.